Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

OAZisCare, digitally powered by DocquityCare, has advanced patient education and adherence for cancer care and RSV vaccines since 2024 The collaboration helps tackle Southeast Asia's healthcare needs, ...

Under direction of Health Secretary Robert F. Kennedy Jr., the CDC is considering changes to its recommendations on vaccines ...

A panel of federal health experts recommended expanded vaccine options for several diseases, including RSV, meningitis, and chikungunya.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

A significant change is coming to GP surgeries, benefiting millions of people aged 75-79. The NHS is expanding its free ...

A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...

NHS will expand free life-saving jabs in a bid to fight a dangerous virus with flu-like symptoms, which threatens to sweep ...

Clinical trials have shown that the RSV vaccine reduces symptoms by around 80 per cent, significantly lowering the risk of ...

In an effort to get more vulnerable people vaccinated against the virus the Government will allow hundreds of community ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...